By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Novo Nordisk Inc. was sued Friday by five former employees who say the pharmaceutical company mismanages its $2.3 billion ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO ...

Novo Nordisk is doubling down on its investment in genetic medicine-based biotechs, inking a new collaboration with a lipid ...

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 13 September 2024, Novo Nordisk has since 6 February 2024 ...

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

DOWN BALLOT — The Forward Majority super PAC has surged its planned spending to $45 million to elect Democrats to statehouses ...